Abstract
Abstract: Sickle Cell Disease is one of the most common genetic disorders in the United States and is incredibly prevalent throughout Africa and the Middle East. By 2050, the annual number of newborns with Sickle Cell Disease is projected to increase by 33%. A similar story can be told about Beta-Thalassemia: another hemoglobinopathy that has no standard treatment. The future of treating hemoglobinopathies looks bleak and more research must be done to prevent fatalities and the lifelong problems associated with it now. Sickle Cell Disease and Beta Thalassemia have one defining similarity: they are both monogenic disorders. This unique characteristic of having a single gene variation allows them to be the ideal candidate for one of the newest breakthroughs in biotechnology: target genome editing. As of now, there are three major competitors in the field, Zinc Finger Nuclease (ZFN), Transcription Activator-like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) target genome editing. Here I summarize the possibilities target genome editing provides in terms of research and a potential treatment for both Sickle Cell disease and Beta Thalassemia with a focus on comparing the three target genome editing technologies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal for Research in Applied Science and Engineering Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
